Acacia Research Corporation (Nasdaq:ACTG) announced today that a
subsidiary has acquired the rights to a patent for intraluminal device
technology.
“Acacia is rapidly
becoming the leader in technology licensing and we continue to grow our
base of future revenues by adding new patent portfolios”
"As Acacia's licensing success grows, more patent owners are selecting
us as their partner for the licensing of their patented technologies,"
commented Paul Ryan, Acacia Chairman and CEO. "Acacia is rapidly
becoming the leader in technology licensing and we continue to grow our
base of future revenues by adding new patent portfolios," concluded Mr.
Ryan.
This patented technology generally relates to securing intraluminal
devices, such as stent grafts, in the body.
Scaling organ‑chip technology for human‑relevant drug discovery